2型糖尿病血瘀证血管内皮细胞损伤模型的研究
|
摘要
研究目的
建立2型糖尿病血瘀证的血管内皮细胞损伤模型,为中医学病证结合细胞模型的研究提供方法学上的借鉴。实验内容包括两部分,第一部分进行糖尿病血瘀证血管内皮细胞损伤模型的研究,体现“同病异证”的特点;第二部分进行高血压病血瘀证和糖尿病血瘀证细胞损伤模型的比较研究,探讨“异病同证”的差异。
第一部分2型糖尿病血瘀证血管内皮细胞损伤模型的研究
实验1.2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)的细胞活性和形态的影响
目的:观察2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)的细胞活性和细胞形态的影响。
方法:ECV-304传代后取对数生长期细胞干预分组如下:N组(正常对照组)、H组(健康人血清干预)、MD组(糖尿病血瘀证患者血清干预)和MND组(糖尿病非血瘀证患者血清干预)。其中糖尿病血瘀证和非血瘀证患者血清各有3个浓度:5%,10%,20%。采用MTT法在全自动酶标仪上于570nm处测定吸光值,应用倒置相差显微镜、扫描电镜和透射电镜观察细胞形态的变化。
结果:①MTT法检测细胞活性,5%浓度:MD组的OD值(0.94±0.14)较H组(1.60±0.17)明显降低,差异有统计学意义(P＜0.001);10%浓度:MD组的OD值(0.88±0.11)较H组(1.34±0.14)明显降低,差异有统计学意义(P＜0.001)。②电镜下MD组细胞和N组的细胞形态上具有明显差异。倒置相差显微镜观察发现:MD组的细胞由圆形居多变为多角形或椭圆形居多,伴间隙增宽;扫描电镜观察发现:MD组细胞收缩分离成为放射星状体,细胞表面有大小不一的圆形凹陷或突起;透射电镜观察发现:MD组胞浆内所含的吞饮泡较N组多,粗面内质网扩张伴数目减少,核糖体部分丢失。平面内质网明显扩张,线粒体肿胀,嵴消失。
结论:10%浓度的2型糖尿病血瘀证患者血清严重损伤体外培养的正常人脐静脉内皮细胞(ECV-304),造成细胞活性降低和细胞形态改变。
实验2.2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)内分泌功能的影响
目的:观察2型糖尿病血瘀证患者血清干预ECV-304对其内分泌功能的影响。
方法:细胞干预分组方法同实验1。应用放免法测定内皮素(ET)含量,应用硝酸还原酶测定一氧化氮(NO)含量;利用双抗夹心ELISA法检测各组细胞培养上清液中内皮细胞蛋白C受体(EPCR)、血管内假性血友病因子(vWF)和血栓调节蛋白(TM)的含量。
结果:①MD组的ET水平(286.03±24.03)比N组(77.88±10.07)升高,差异有统计学意义(P＜0.001);MD组的ET水平(286.03±24.03)比MND组(236.22±15.89)升高,差异有统计学意义(P＜0.001)。②MD组的NO水平(22.37±3.30)比N组(52.97±8.51)降低,差异有统计学意义(P＜0.001);MD组的NO水平(22.37±3.30)和MND组(24.55±3.79)相比差异没有统计学意义(P＞0.05)。③内皮细胞经过患者血清损伤后,MD组分泌的EPCR含量(189.66±11.76)比N组(113.94±16.04)升高,差异有统计学意义(P＜0.001);MND组分泌量(216.24±15.86)较MD组(189.66±11.76)升高,差异有统计学意义(P＜0.001)。④损伤后MD组分泌的vWF含量(79.94±8.52)比N组(51.09±9.92)升高,差异有统计学意义(P＜0.001);MND组分泌量(78.85±10.17)较MD组(79.94±8.52)减少,但差异没有统计学意义(P＞0.05)。⑤损伤后MD组分泌的TM含量(29.25±5.16)比N组的(18.47±2.59)升高,差异有统计学意义(P＜0.001);MND组分泌量(26.40±4.36)较MD组(29.25+5.16)减少,但差异没有统计学意义(P＞0.05)。
结论:糖尿病血瘀证患者血清干预ECV-304后可以造成血管内皮细胞功能损伤,表现在内分泌功能的变化上,其中最为明显的是释放ET增加,而NO分泌减少,ET和NO二者之间失去平衡;反映内皮细胞内分泌功能的细胞因子如EPCR、vWF和TM等细胞损伤标志物的含量也显著上升,尤其是EPCR增加最为明显,提示糖尿病血瘀证患者血清对上述因子的表达起作用,说明糖尿病血瘀证患者血清干预正常的血管内皮细胞,可以造成内分泌功能紊乱。
实验3.2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)骨架及胞浆内游离钙的影响
目的:探讨2型糖尿病血瘀证患者血清干预ECV-304对细胞骨架微丝及胞浆内游离钙浓度的影响。
方法:细胞干预分组方法同实验1。应用激光扫描共聚焦显微镜,采用Fluo-3/AM作为荧光指示剂观察细胞内游离钙浓度的变化,采用荧光探针标记的鬼笔环肽染色法观察细胞肌动蛋白微丝分布的差异。
结果:①胞浆内游离钙浓度以荧光强度来表示,MD组胞浆内荧光分布不均匀,呈网状或团块状,荧光强度(127.53±10.49)高于N组(92.05±6.41),差异有统计学意义(P＜0.001);MD组的荧光强度也高于MND组(108.26±7.35),差异有统计学意义(P＜0.001)。②细胞骨架微丝经过特异性抗体染色后,N组和H组细胞分布多规则清晰,彼此连接,附着在细胞内特定部位,保持着细胞的正常外形;MD组可见细胞外形发生皱缩,微丝断裂,排列紊乱,少部分区域缺失;MND组可见细胞外形发生皱缩,微丝断裂但排列较为规则,部分可见丝网状有序排列。
结论:糖尿病血瘀证患者血清严重损伤体外培养的正常ECV-304,表现在胞浆内游离钙浓度的升高和细胞骨架微丝分布的变化。由于细胞内钙离子通过微丝结合蛋白来调节细胞骨架的装配与分解,高钙情况下该蛋白可使长微丝切断成片段,本研究中细胞内钙离子的升高可能介导了血瘀证血清对细胞骨架的损伤作用。
实验4.血府逐瘀汤及丹参酮ⅡA(TanⅡA)对抗糖尿病血瘀证患者血清致内皮功能障碍的影响
目的:观察血府逐瘀汤复方及丹参酮ⅡA对抗糖尿病血瘀证患者血清致内皮功能障碍的影响。
方法:N组和MD组分组方法同实验1,还有MDB组(10%2型糖尿病血瘀证患者血清和血府逐瘀汤复方药物血清共同干预24h)和MDT组(10%2型糖尿病血瘀证患者血清和TanⅡA共同干预24h)。其中血府逐瘀汤复方药物血清各有3个浓度:20%,10%和5%;TanⅡA各有3个浓度:20μg/ml,10μg/ml和5μg/ml。利用MTT法检测吸光值,利用倒置相差显微镜、扫描电镜和透射电镜观察细胞形态。根据结果对药物选取最佳作用浓度后进一步测定细胞分泌的ET和NO含量、EPCR、vWF、TM的含量。利用激光扫描共聚焦显微镜观察细胞内游离钙浓度和细胞骨架微丝的变化。
结果:①倒置相差显微镜观察发现:MDB组的细胞恢复椭圆形紧密排列,边界较清楚,MDT组细胞无重叠生长现象,细胞碎片较少;扫描电镜观察发现:MDB组细胞之间有间隙,但仍然有突起连接,细胞表面有大小不一的圆形凹陷或突起;MDT组中多数细胞收缩分离呈现放射星状体;透射电镜观察发现:MDB组细胞粗面内质网数目较少,不扩张,其上附着的核糖体不丢失,线粒体数目减少,其双层膜及内嵴结构清晰,在核未见特殊改变;MDT组透射电镜结果与MDB组接近。②MDT组的OD值(1.11±0.12)较MD组(0.66±0.09)显著升高,差异有统计学意义(P＜0.001),以TanⅡA的浓度为10μg/ml时差异最为显著(P＜0.001);MDB组的OD值(0.96±0.15)较MD组(0.55±0.09)显著升高,差异有统计学意义(P＜0.001)。以血府逐瘀汤复方药物血清浓度为10%时差异最为显著(P＜0.001)。根据MTT和形态观察,选取最佳作用浓度,糖尿病血瘀证患者血清浓度为10%,TanⅡA的浓度为10μg/ml;③MDT组的ET水平(143.85±13.05)比MD组(286.03±24.03)降低,差异有统计学意义(P＜0.001);MDB组的ET水平(191.23±12.17)比MD组(286.03±24.03)降低,差异有统计学意义(P＜0.001);④MDT组的NO水平(46.86±8.12)比MD组(22.37±3.30)降低,差异有统计学意义(P＜0.001);MDB组的NO水平(29.41±4.46)比MD组(22.37±3.30)降低,但差异没有统计学意义(P＞0.05);⑤MDT组分泌的EPCR含量(132.22±13.28)与MD组(189.66±11.76)相比减少,差异有统计学意义(P＜0.001);MDB组分泌的EPCR含量(122.80±14.37)与MD组(189.66±11.76)相比也有减少,差异有统计学意义(P＜0.001)。⑥MDT组分泌的vWF含量(104.19±10.45)比MD组(79.94±8.52)升高,但差异没有统计学意义(P＞0.05);MDB组分泌的vWF含量(62.41±9.44)与MD组(79.94±8.52)相比减少,差异有统计学意义(P＜0.001)。⑦MDT组分泌的TM含量(27.14±4.61)比MD组(29.25±5.16)降低,但差异没有统计学意义(P＞0.05);MDB组分泌的TM含量(22.30±3.18)与MD组(29.25±5.16)降低,差异有统计学意义(P＜0.001)。⑧MDT组荧光强度(154.96±7.90)高于MD组(127.53±10.49),差异有统计学意义(P＜0.001);MDB组荧光强度(92.61±7.06)低于MD组(127.53±10.49),差异也有统计学意义(P＜0.001);⑨MDB组和MDT组细胞外形接近正常,骨架微丝较少但排列规则,分布清晰,和MD组有明显差异。
结论:10%浓度血府逐瘀汤复方药物血清和10μg/ml中药丹参酮ⅡA可以有效对抗糖尿病血瘀证患者血清干预ECV-304造成的内皮功能障碍,减少患者血清对于细胞的损伤,对血管内皮细胞起到一定的保护作用,从而证实了在体外环境下,用于试验的中药复方和单味中药有效成分对细胞损伤模型具有的保护作用。也从药物的角度反证了细胞损伤模型的成功建立。
第二部分高血压病和2型糖尿病血瘀证血管内皮细胞损伤模型的比较研究
目的:通过高血压病和2型糖尿病血瘀证血管内皮细胞损伤模型的比较,为异病同证理论提供实验依据。
方法:N组、H组、MD组、MDB和MDT分组方法同第一部分,还有MH组(10%高血压病血瘀证患者血清干预)、MHB组(10%高血压病血瘀证患者血清和血府逐瘀汤复方药物血清共同干预24h)和MHT组(10%高血压病血瘀证患者血清和TanⅡA共同干预24h)。实验方法同第一部分。
结果:①MH组的OD值(0.98±0.12)高于MD组(0.88±0.11),但差异没有统计学意义(P＞0.05);②MH组分泌的ET含量(177.62±15.77)低于MD组(286.03±24.03),差异有统计学意义(P＜0.001);③MH组分泌的NO含量(32.61±6.76)高于MD组(22.37±3.30),差异有统计学意义(P＜0.001);④MH组分泌的EPCR含量(168.32±21.94)低于MD组(189.66±11.76),差异有统计学意义(P＜0.001);⑤MH组分泌的vWF含量(80.17±10.25)高于MD组(79.94±8.52),差异有统计学意义(P＜0.001);⑥MH组分泌的TM含量(28.36±4.94)略低于MD组(29.25±5.16),但差异没有统计学意义(P＞0.05);⑦MH组荧光强度(156.78±8.22)高于MD组(127.53±10.48),差异有统计学意义(P＜0.001);⑧MH组可见细胞间隙加大,微丝较少但排列较为规则,部分可见丝网状有序排列;与MD组骨架微丝分布差异显著。
结论:高血压病患者血清和糖尿病患者血清干预正常培养的ECV-304都可以造成血管内皮细胞的损伤,在细胞形态和细胞活性、细胞内分泌功能(TM)等方面没有明显的差异,此为“证”同,可以作为“血瘀证”共同的病理生理学基础模型;而在异“病”方面,由于糖尿病和高血压病的血清也存在不同程度的差异,对细胞损伤的差异集中表现为细胞内分泌功能(EPCR和vWF、ET和NO)和细胞内钙离子的浓度变化等方面,这些差异可体现为“病”异的基础。前后结合后则明确体现了异“病”同“证”的特点,深入机制探讨将有可能对血瘀证的微观辨证提供依据。
Objective
To establish the vascular endothelial cell(VEC) injury model of syndrome(BSS) associated with diabetes(DB),to observe the model cells' change of cytoactive,shape,ultrastructure and function,and to provide reference in the methodology for the establishment of traditional Chinese medicine(TCM) cell model based on integration of disease and syndrome.
PartⅠ.Research on the injury model by the serum of DB patients with BSS
1.Effects of ECV-304 incubated by the serum of patients with BSS associated with diabetes
[Objective]To observe the effects of ECV-304 incubated by the serum of patients with BSS associated with diabetes.[Methods]ECV-304 were obtained by cultured conventionally.It was divided into 4 groups,ECV-304 cultured with DMEM(Group N),with the serum of healthy person(Group H),with the serum of patients with BSS associated with diabetes(Group MD) and the serum of diabetes patients with no-BSS(Group MND).The cytoactive of ECV-304 were assayed by MTT chromatometry,and morpHological changes were identified by light microscope and electron microscopy.All groups were measured.[Results]①There was a statistically significant difference(P＜0.001)regarding the OD in the MD Group and H Group.②By the inverse phase contrast microscope,we discovered a significant difference between the Group MD and Group MND.[Conclusion]The serum of patients with BSS associated with diabetes could injury ECV-304 of the cytoactive and shape.
2.Preliminary research on the mechanisms of injury ECV-304 by the serum of patients with BSS associated with diabetes on endothelial dysfunction
[Objective]To explore the mechanisms of ECV-304 incubated by the serum of patients with BSS associated with diabetes.[Methods]ECV-304 was divided into 4 groups the same as the 1~(st) experiment.The nitric oxide(NO) excreted by model cells was assayed by nitric acid deoxidizing enzyme method,and the endothelin(ET) was assayed by non-balance method.The injury symbols of VEC:vWF,TM and EPCR excreted by model cells were assayed by enzyme-linked immunosorbent assay (ELISA).All groups were measured.[Results]①There was a significant difference(P＜0.001) regarding the ET excreted by ECV-304 between the Group MD and Group H,Group N,Group MND.②There was a significant difference(P＜0.001) regarding the NO excreted by ECV-304 between the Group MD and Group N,Group H.③There was a significant difference(P＜0.001) regarding the EPCR excreted by ECV-304 between the Group MD and Group N,Group H,Group MND.④There was a significant difference(P＜0.001) regarding the vWF excreted by ECV-304 between the Group MD and Group N.⑤And the same condition of TM happened between the Group MDand the Group N significantly(P＜0.001).[Conclusion]The serum of patients with BSS associated with diabetes could injury ECV-304 and caused endothelial dysfunction.It was possible that BSS influnenced the expression of molecules in vascular endothelial cells.
3.Preliminary research on the mechanisms of injury ECV-304 by the serum of patients with BSS associated with diabetes on intracellular free calcium([Ca~(2+)]i) and cytoskeleton
[Objective]To explore the mechanisms of ECV-304 incubated by the serum of patients with BSS associated with diabetes.[Methods]ECV-304 was divided into 4 groups the same as the 1~(st) experiment.Model cells' intracellular free calcium([Ca~(2+)]i) and cytoskeleton were assayed by laser scanning confocal microscope(LSCM).All groups were measured.[Results]①There was a significant difference(P＜0.001) regarding the intracellular calcium concentration([Ca~(2+)]i) of ECV-304 between the Group MD and Group H,Group N,Group MND.②by the cytoskeleton,the Group MD was distinctly different with the Group MND.[Conclusion]The serum of patients with BSS associated with diabetes could injury ECV-304 and caused Model cells' intracellular free calcium([Ca~(2+)]i) and cytoskeleton change.
4.Protective effects of Xuefn Zhuyu decoction and TanⅡA on the injury model by the serum of patients with BSS associated with diabetes on endothelial dysfunction
[Objective]To observe the protective effectes of Xuefu Zhuyu decoction and TanⅡA on the cellar injury model by the serum of patients with BSS associated with diabetes on endothelia dysfunction.[Methods]ECV-304 were obtained by cultured conventionally.It was divided into 4 groups,Group N and Group MD is the same as 1~(st) experiment,the group incubated with the serum of patients with BSS associated with diabetes and the mice serum of Xuefu Zhuyu decoction(Group MDB),the group with the serum of diabetes patients with BSS and TanⅡA(Group MDT).The activeness of ECV-304 were assayed by MTT chromatometry,and morpHological changes were identified by light microscope and electron microscopy.The nitric oxide(NO) excreted by model cells was assayed by nitric acid deoxidizing enzyme method,and the endothelin(ET) was assayed by non-balance method.The injury symbols of VEC:vWF,TM and EPCR excreted by model cells were assayed by enzyme-linked immunosorbent assay(ELISA).Model cells' intracellular free calcium ([Ca~(2+)]i) and cytoskeleton were assayed by laser scanning confocal microscope(LSCM).All groups were measured.[Results]①By the inverse pHase contrast microscope,we discovered that the Group MDB and Group MDT is the same shape as the Group N.②There was a significant difference(P＜0.001)of the secretion of OD,NO,ET,EPCR,vWF,TM and intracellular calcium concentration between the Group MDB and the Group MD.③There was a significant difference(P＜0.001) of the secretion of OD,NO and ET between the Group MDT and the Group MD,but no differences in the intracellular calcium concentration and the injury symbols.④by the cytoskeleton,the Group MDB and Group MDT were distinctly different with the Group MD.[Conclusion]The Xuefu Zhuyu decoction and TanⅡA had the protective effectes on the cellar injury model by the serum of patients with BSS associated with diabetes on endothelia dysfunction and from the point of medicine,they could recover endothedial dysfunction induced by the cellar injury model the medicine.
PartⅡ.Differences between injury models by the serum of EH patients with BSS and by the serum of DB patients with BSS
[Objective]To investigate the differences between injury models by the serum of EH patients with BSS and by the serum of DB patients with BSS.[Methods] ECV-304 were obtained by cultured conventionally.It was divided into 4 groups. Group N,Group H and Group MD is the same as 1~(st) experiment,the group incubated with the serum of patients with BSS associated with EH(Group MH).The activeness of ECV-304 were assayed by MTT chromatometry,and morpHological changes were identified by light microscope and electron microscopy.The nitric oxide(NO) excreted by model cells was assayed by nitric acid deoxidizing enzyme method,and the endothelin(ET) was assayed by non-balance method.The injury symbols of VEC: vWF,TM and EPCR excreted by model cells were assayed by enzyme-linked immunosorbent assay(ELISA).Model cells' intracellular free calcium([Ca~(2+)]i) and cytoskeleton were assayed by laser scanning confocal microscope(LSCM).All groups were measured.[Results]There was a significant difference of the secretion of OD, NO,ET,EPCR,vWF,intracellular calcium concentration and cytoskeleton between the Group MD and the Group MH.[Conclusion]The results clearly show that the changes between the Group MD and the Group MH is partly related to the basis of BSS.Furthermore,by the example of BSS,it can partially explain the mechanism of "different disease and same syndrome" in Traditional Chinese Medicine.
建立2型糖尿病血瘀证的血管内皮细胞损伤模型,为中医学病证结合细胞模型的研究提供方法学上的借鉴。实验内容包括两部分,第一部分进行糖尿病血瘀证血管内皮细胞损伤模型的研究,体现“同病异证”的特点;第二部分进行高血压病血瘀证和糖尿病血瘀证细胞损伤模型的比较研究,探讨“异病同证”的差异。
第一部分2型糖尿病血瘀证血管内皮细胞损伤模型的研究
实验1.2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)的细胞活性和形态的影响
目的:观察2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)的细胞活性和细胞形态的影响。
方法:ECV-304传代后取对数生长期细胞干预分组如下:N组(正常对照组)、H组(健康人血清干预)、MD组(糖尿病血瘀证患者血清干预)和MND组(糖尿病非血瘀证患者血清干预)。其中糖尿病血瘀证和非血瘀证患者血清各有3个浓度:5%,10%,20%。采用MTT法在全自动酶标仪上于570nm处测定吸光值,应用倒置相差显微镜、扫描电镜和透射电镜观察细胞形态的变化。
结果:①MTT法检测细胞活性,5%浓度:MD组的OD值(0.94±0.14)较H组(1.60±0.17)明显降低,差异有统计学意义(P＜0.001);10%浓度:MD组的OD值(0.88±0.11)较H组(1.34±0.14)明显降低,差异有统计学意义(P＜0.001)。②电镜下MD组细胞和N组的细胞形态上具有明显差异。倒置相差显微镜观察发现:MD组的细胞由圆形居多变为多角形或椭圆形居多,伴间隙增宽;扫描电镜观察发现:MD组细胞收缩分离成为放射星状体,细胞表面有大小不一的圆形凹陷或突起;透射电镜观察发现:MD组胞浆内所含的吞饮泡较N组多,粗面内质网扩张伴数目减少,核糖体部分丢失。平面内质网明显扩张,线粒体肿胀,嵴消失。
结论:10%浓度的2型糖尿病血瘀证患者血清严重损伤体外培养的正常人脐静脉内皮细胞(ECV-304),造成细胞活性降低和细胞形态改变。
实验2.2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)内分泌功能的影响
目的:观察2型糖尿病血瘀证患者血清干预ECV-304对其内分泌功能的影响。
方法:细胞干预分组方法同实验1。应用放免法测定内皮素(ET)含量,应用硝酸还原酶测定一氧化氮(NO)含量;利用双抗夹心ELISA法检测各组细胞培养上清液中内皮细胞蛋白C受体(EPCR)、血管内假性血友病因子(vWF)和血栓调节蛋白(TM)的含量。
结果:①MD组的ET水平(286.03±24.03)比N组(77.88±10.07)升高,差异有统计学意义(P＜0.001);MD组的ET水平(286.03±24.03)比MND组(236.22±15.89)升高,差异有统计学意义(P＜0.001)。②MD组的NO水平(22.37±3.30)比N组(52.97±8.51)降低,差异有统计学意义(P＜0.001);MD组的NO水平(22.37±3.30)和MND组(24.55±3.79)相比差异没有统计学意义(P＞0.05)。③内皮细胞经过患者血清损伤后,MD组分泌的EPCR含量(189.66±11.76)比N组(113.94±16.04)升高,差异有统计学意义(P＜0.001);MND组分泌量(216.24±15.86)较MD组(189.66±11.76)升高,差异有统计学意义(P＜0.001)。④损伤后MD组分泌的vWF含量(79.94±8.52)比N组(51.09±9.92)升高,差异有统计学意义(P＜0.001);MND组分泌量(78.85±10.17)较MD组(79.94±8.52)减少,但差异没有统计学意义(P＞0.05)。⑤损伤后MD组分泌的TM含量(29.25±5.16)比N组的(18.47±2.59)升高,差异有统计学意义(P＜0.001);MND组分泌量(26.40±4.36)较MD组(29.25+5.16)减少,但差异没有统计学意义(P＞0.05)。
结论:糖尿病血瘀证患者血清干预ECV-304后可以造成血管内皮细胞功能损伤,表现在内分泌功能的变化上,其中最为明显的是释放ET增加,而NO分泌减少,ET和NO二者之间失去平衡;反映内皮细胞内分泌功能的细胞因子如EPCR、vWF和TM等细胞损伤标志物的含量也显著上升,尤其是EPCR增加最为明显,提示糖尿病血瘀证患者血清对上述因子的表达起作用,说明糖尿病血瘀证患者血清干预正常的血管内皮细胞,可以造成内分泌功能紊乱。
实验3.2型糖尿病血瘀证患者血清对人脐静脉内皮细胞(ECV-304)骨架及胞浆内游离钙的影响
目的:探讨2型糖尿病血瘀证患者血清干预ECV-304对细胞骨架微丝及胞浆内游离钙浓度的影响。
方法:细胞干预分组方法同实验1。应用激光扫描共聚焦显微镜,采用Fluo-3/AM作为荧光指示剂观察细胞内游离钙浓度的变化,采用荧光探针标记的鬼笔环肽染色法观察细胞肌动蛋白微丝分布的差异。
结果:①胞浆内游离钙浓度以荧光强度来表示,MD组胞浆内荧光分布不均匀,呈网状或团块状,荧光强度(127.53±10.49)高于N组(92.05±6.41),差异有统计学意义(P＜0.001);MD组的荧光强度也高于MND组(108.26±7.35),差异有统计学意义(P＜0.001)。②细胞骨架微丝经过特异性抗体染色后,N组和H组细胞分布多规则清晰,彼此连接,附着在细胞内特定部位,保持着细胞的正常外形;MD组可见细胞外形发生皱缩,微丝断裂,排列紊乱,少部分区域缺失;MND组可见细胞外形发生皱缩,微丝断裂但排列较为规则,部分可见丝网状有序排列。
结论:糖尿病血瘀证患者血清严重损伤体外培养的正常ECV-304,表现在胞浆内游离钙浓度的升高和细胞骨架微丝分布的变化。由于细胞内钙离子通过微丝结合蛋白来调节细胞骨架的装配与分解,高钙情况下该蛋白可使长微丝切断成片段,本研究中细胞内钙离子的升高可能介导了血瘀证血清对细胞骨架的损伤作用。
实验4.血府逐瘀汤及丹参酮ⅡA(TanⅡA)对抗糖尿病血瘀证患者血清致内皮功能障碍的影响
目的:观察血府逐瘀汤复方及丹参酮ⅡA对抗糖尿病血瘀证患者血清致内皮功能障碍的影响。
方法:N组和MD组分组方法同实验1,还有MDB组(10%2型糖尿病血瘀证患者血清和血府逐瘀汤复方药物血清共同干预24h)和MDT组(10%2型糖尿病血瘀证患者血清和TanⅡA共同干预24h)。其中血府逐瘀汤复方药物血清各有3个浓度:20%,10%和5%;TanⅡA各有3个浓度:20μg/ml,10μg/ml和5μg/ml。利用MTT法检测吸光值,利用倒置相差显微镜、扫描电镜和透射电镜观察细胞形态。根据结果对药物选取最佳作用浓度后进一步测定细胞分泌的ET和NO含量、EPCR、vWF、TM的含量。利用激光扫描共聚焦显微镜观察细胞内游离钙浓度和细胞骨架微丝的变化。
结果:①倒置相差显微镜观察发现:MDB组的细胞恢复椭圆形紧密排列,边界较清楚,MDT组细胞无重叠生长现象,细胞碎片较少;扫描电镜观察发现:MDB组细胞之间有间隙,但仍然有突起连接,细胞表面有大小不一的圆形凹陷或突起;MDT组中多数细胞收缩分离呈现放射星状体;透射电镜观察发现:MDB组细胞粗面内质网数目较少,不扩张,其上附着的核糖体不丢失,线粒体数目减少,其双层膜及内嵴结构清晰,在核未见特殊改变;MDT组透射电镜结果与MDB组接近。②MDT组的OD值(1.11±0.12)较MD组(0.66±0.09)显著升高,差异有统计学意义(P＜0.001),以TanⅡA的浓度为10μg/ml时差异最为显著(P＜0.001);MDB组的OD值(0.96±0.15)较MD组(0.55±0.09)显著升高,差异有统计学意义(P＜0.001)。以血府逐瘀汤复方药物血清浓度为10%时差异最为显著(P＜0.001)。根据MTT和形态观察,选取最佳作用浓度,糖尿病血瘀证患者血清浓度为10%,TanⅡA的浓度为10μg/ml;③MDT组的ET水平(143.85±13.05)比MD组(286.03±24.03)降低,差异有统计学意义(P＜0.001);MDB组的ET水平(191.23±12.17)比MD组(286.03±24.03)降低,差异有统计学意义(P＜0.001);④MDT组的NO水平(46.86±8.12)比MD组(22.37±3.30)降低,差异有统计学意义(P＜0.001);MDB组的NO水平(29.41±4.46)比MD组(22.37±3.30)降低,但差异没有统计学意义(P＞0.05);⑤MDT组分泌的EPCR含量(132.22±13.28)与MD组(189.66±11.76)相比减少,差异有统计学意义(P＜0.001);MDB组分泌的EPCR含量(122.80±14.37)与MD组(189.66±11.76)相比也有减少,差异有统计学意义(P＜0.001)。⑥MDT组分泌的vWF含量(104.19±10.45)比MD组(79.94±8.52)升高,但差异没有统计学意义(P＞0.05);MDB组分泌的vWF含量(62.41±9.44)与MD组(79.94±8.52)相比减少,差异有统计学意义(P＜0.001)。⑦MDT组分泌的TM含量(27.14±4.61)比MD组(29.25±5.16)降低,但差异没有统计学意义(P＞0.05);MDB组分泌的TM含量(22.30±3.18)与MD组(29.25±5.16)降低,差异有统计学意义(P＜0.001)。⑧MDT组荧光强度(154.96±7.90)高于MD组(127.53±10.49),差异有统计学意义(P＜0.001);MDB组荧光强度(92.61±7.06)低于MD组(127.53±10.49),差异也有统计学意义(P＜0.001);⑨MDB组和MDT组细胞外形接近正常,骨架微丝较少但排列规则,分布清晰,和MD组有明显差异。
结论:10%浓度血府逐瘀汤复方药物血清和10μg/ml中药丹参酮ⅡA可以有效对抗糖尿病血瘀证患者血清干预ECV-304造成的内皮功能障碍,减少患者血清对于细胞的损伤,对血管内皮细胞起到一定的保护作用,从而证实了在体外环境下,用于试验的中药复方和单味中药有效成分对细胞损伤模型具有的保护作用。也从药物的角度反证了细胞损伤模型的成功建立。
第二部分高血压病和2型糖尿病血瘀证血管内皮细胞损伤模型的比较研究
目的:通过高血压病和2型糖尿病血瘀证血管内皮细胞损伤模型的比较,为异病同证理论提供实验依据。
方法:N组、H组、MD组、MDB和MDT分组方法同第一部分,还有MH组(10%高血压病血瘀证患者血清干预)、MHB组(10%高血压病血瘀证患者血清和血府逐瘀汤复方药物血清共同干预24h)和MHT组(10%高血压病血瘀证患者血清和TanⅡA共同干预24h)。实验方法同第一部分。
结果:①MH组的OD值(0.98±0.12)高于MD组(0.88±0.11),但差异没有统计学意义(P＞0.05);②MH组分泌的ET含量(177.62±15.77)低于MD组(286.03±24.03),差异有统计学意义(P＜0.001);③MH组分泌的NO含量(32.61±6.76)高于MD组(22.37±3.30),差异有统计学意义(P＜0.001);④MH组分泌的EPCR含量(168.32±21.94)低于MD组(189.66±11.76),差异有统计学意义(P＜0.001);⑤MH组分泌的vWF含量(80.17±10.25)高于MD组(79.94±8.52),差异有统计学意义(P＜0.001);⑥MH组分泌的TM含量(28.36±4.94)略低于MD组(29.25±5.16),但差异没有统计学意义(P＞0.05);⑦MH组荧光强度(156.78±8.22)高于MD组(127.53±10.48),差异有统计学意义(P＜0.001);⑧MH组可见细胞间隙加大,微丝较少但排列较为规则,部分可见丝网状有序排列;与MD组骨架微丝分布差异显著。
结论:高血压病患者血清和糖尿病患者血清干预正常培养的ECV-304都可以造成血管内皮细胞的损伤,在细胞形态和细胞活性、细胞内分泌功能(TM)等方面没有明显的差异,此为“证”同,可以作为“血瘀证”共同的病理生理学基础模型;而在异“病”方面,由于糖尿病和高血压病的血清也存在不同程度的差异,对细胞损伤的差异集中表现为细胞内分泌功能(EPCR和vWF、ET和NO)和细胞内钙离子的浓度变化等方面,这些差异可体现为“病”异的基础。前后结合后则明确体现了异“病”同“证”的特点,深入机制探讨将有可能对血瘀证的微观辨证提供依据。
Objective
To establish the vascular endothelial cell(VEC) injury model of syndrome(BSS) associated with diabetes(DB),to observe the model cells' change of cytoactive,shape,ultrastructure and function,and to provide reference in the methodology for the establishment of traditional Chinese medicine(TCM) cell model based on integration of disease and syndrome.
PartⅠ.Research on the injury model by the serum of DB patients with BSS
1.Effects of ECV-304 incubated by the serum of patients with BSS associated with diabetes
[Objective]To observe the effects of ECV-304 incubated by the serum of patients with BSS associated with diabetes.[Methods]ECV-304 were obtained by cultured conventionally.It was divided into 4 groups,ECV-304 cultured with DMEM(Group N),with the serum of healthy person(Group H),with the serum of patients with BSS associated with diabetes(Group MD) and the serum of diabetes patients with no-BSS(Group MND).The cytoactive of ECV-304 were assayed by MTT chromatometry,and morpHological changes were identified by light microscope and electron microscopy.All groups were measured.[Results]①There was a statistically significant difference(P＜0.001)regarding the OD in the MD Group and H Group.②By the inverse phase contrast microscope,we discovered a significant difference between the Group MD and Group MND.[Conclusion]The serum of patients with BSS associated with diabetes could injury ECV-304 of the cytoactive and shape.
2.Preliminary research on the mechanisms of injury ECV-304 by the serum of patients with BSS associated with diabetes on endothelial dysfunction
[Objective]To explore the mechanisms of ECV-304 incubated by the serum of patients with BSS associated with diabetes.[Methods]ECV-304 was divided into 4 groups the same as the 1~(st) experiment.The nitric oxide(NO) excreted by model cells was assayed by nitric acid deoxidizing enzyme method,and the endothelin(ET) was assayed by non-balance method.The injury symbols of VEC:vWF,TM and EPCR excreted by model cells were assayed by enzyme-linked immunosorbent assay (ELISA).All groups were measured.[Results]①There was a significant difference(P＜0.001) regarding the ET excreted by ECV-304 between the Group MD and Group H,Group N,Group MND.②There was a significant difference(P＜0.001) regarding the NO excreted by ECV-304 between the Group MD and Group N,Group H.③There was a significant difference(P＜0.001) regarding the EPCR excreted by ECV-304 between the Group MD and Group N,Group H,Group MND.④There was a significant difference(P＜0.001) regarding the vWF excreted by ECV-304 between the Group MD and Group N.⑤And the same condition of TM happened between the Group MDand the Group N significantly(P＜0.001).[Conclusion]The serum of patients with BSS associated with diabetes could injury ECV-304 and caused endothelial dysfunction.It was possible that BSS influnenced the expression of molecules in vascular endothelial cells.
3.Preliminary research on the mechanisms of injury ECV-304 by the serum of patients with BSS associated with diabetes on intracellular free calcium([Ca~(2+)]i) and cytoskeleton
[Objective]To explore the mechanisms of ECV-304 incubated by the serum of patients with BSS associated with diabetes.[Methods]ECV-304 was divided into 4 groups the same as the 1~(st) experiment.Model cells' intracellular free calcium([Ca~(2+)]i) and cytoskeleton were assayed by laser scanning confocal microscope(LSCM).All groups were measured.[Results]①There was a significant difference(P＜0.001) regarding the intracellular calcium concentration([Ca~(2+)]i) of ECV-304 between the Group MD and Group H,Group N,Group MND.②by the cytoskeleton,the Group MD was distinctly different with the Group MND.[Conclusion]The serum of patients with BSS associated with diabetes could injury ECV-304 and caused Model cells' intracellular free calcium([Ca~(2+)]i) and cytoskeleton change.
4.Protective effects of Xuefn Zhuyu decoction and TanⅡA on the injury model by the serum of patients with BSS associated with diabetes on endothelial dysfunction
[Objective]To observe the protective effectes of Xuefu Zhuyu decoction and TanⅡA on the cellar injury model by the serum of patients with BSS associated with diabetes on endothelia dysfunction.[Methods]ECV-304 were obtained by cultured conventionally.It was divided into 4 groups,Group N and Group MD is the same as 1~(st) experiment,the group incubated with the serum of patients with BSS associated with diabetes and the mice serum of Xuefu Zhuyu decoction(Group MDB),the group with the serum of diabetes patients with BSS and TanⅡA(Group MDT).The activeness of ECV-304 were assayed by MTT chromatometry,and morpHological changes were identified by light microscope and electron microscopy.The nitric oxide(NO) excreted by model cells was assayed by nitric acid deoxidizing enzyme method,and the endothelin(ET) was assayed by non-balance method.The injury symbols of VEC:vWF,TM and EPCR excreted by model cells were assayed by enzyme-linked immunosorbent assay(ELISA).Model cells' intracellular free calcium ([Ca~(2+)]i) and cytoskeleton were assayed by laser scanning confocal microscope(LSCM).All groups were measured.[Results]①By the inverse pHase contrast microscope,we discovered that the Group MDB and Group MDT is the same shape as the Group N.②There was a significant difference(P＜0.001)of the secretion of OD,NO,ET,EPCR,vWF,TM and intracellular calcium concentration between the Group MDB and the Group MD.③There was a significant difference(P＜0.001) of the secretion of OD,NO and ET between the Group MDT and the Group MD,but no differences in the intracellular calcium concentration and the injury symbols.④by the cytoskeleton,the Group MDB and Group MDT were distinctly different with the Group MD.[Conclusion]The Xuefu Zhuyu decoction and TanⅡA had the protective effectes on the cellar injury model by the serum of patients with BSS associated with diabetes on endothelia dysfunction and from the point of medicine,they could recover endothedial dysfunction induced by the cellar injury model the medicine.
PartⅡ.Differences between injury models by the serum of EH patients with BSS and by the serum of DB patients with BSS
[Objective]To investigate the differences between injury models by the serum of EH patients with BSS and by the serum of DB patients with BSS.[Methods] ECV-304 were obtained by cultured conventionally.It was divided into 4 groups. Group N,Group H and Group MD is the same as 1~(st) experiment,the group incubated with the serum of patients with BSS associated with EH(Group MH).The activeness of ECV-304 were assayed by MTT chromatometry,and morpHological changes were identified by light microscope and electron microscopy.The nitric oxide(NO) excreted by model cells was assayed by nitric acid deoxidizing enzyme method,and the endothelin(ET) was assayed by non-balance method.The injury symbols of VEC: vWF,TM and EPCR excreted by model cells were assayed by enzyme-linked immunosorbent assay(ELISA).Model cells' intracellular free calcium([Ca~(2+)]i) and cytoskeleton were assayed by laser scanning confocal microscope(LSCM).All groups were measured.[Results]There was a significant difference of the secretion of OD, NO,ET,EPCR,vWF,intracellular calcium concentration and cytoskeleton between the Group MD and the Group MH.[Conclusion]The results clearly show that the changes between the Group MD and the Group MH is partly related to the basis of BSS.Furthermore,by the example of BSS,it can partially explain the mechanism of "different disease and same syndrome" in Traditional Chinese Medicine.
引文
[1]廖福龙.血瘀证的动物模型现状、问题与展望.中国中西医结合杂志,2002;10(2):888
[2]吴承玉.血瘀证的研究发展脉络与评述.南京中医药大学学报,2004;20(3):133-136
[3]田金洲,王永炎,时晶,朱爱华,黄启福.证候模型研究的思路北京中医药大学学报,2005:28(6):18-21
[4]田金洲,王永炎,徐意,时晶.血瘀证动物模型的种类、评价与研究.北京中医药大学学报,2006;29(6):396-400
[5]徐丽,陈柏楠.血瘀证实验研究概况.山东中医杂志,2005;24(7):445-447
[6]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005;3(11):10-12
[7]葛红颖,陈利国.试论《黄帝内经》对血瘀证的认识.四川中医,2003;21(12):14-15
[8]刘军莲,宋剑南.中医血瘀证本质研究概况.辽宁中医杂志,2006;33(9):1091-1093
[9]陈利国,屈援,葛红颖,胡小勤,聂优爱,何孟栖.补阳还五汤对血瘀证大鼠曲.管内皮细胞黏附分子表达的影响.中草药,2005;36(5):706-709
[10]王奇,陈云波,赖世隆,梁伟雄,温汗淮.血府逐瘀汤对血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响.中国实验方剂学杂志,2002;8(2):12-14
[11]陈利国,胡小勤.论病证结合血瘀证血管内皮细胞损伤模型的建立.中国中西医结合杂志,2007;27(3):271-273
[12]蒋跃绒,殷惠军,刘颖,陈强,陈可冀.血瘀证基础研究的若干思考.中国中医基础医学杂志,2005;11(8):561-563
[13]祝湛予,郭赛珊,梁晓春.对糖尿病中医标准及施治方药的探讨.上海中医药杂志,1982,(6):5
[14]陈利国,马民,屈援,等.糖尿病血瘀证研究进展.中华中医药杂志,2005;20(2):114-116
[15]Isaballa Sudano,Lukas E Spieker,Frank Hermann,et al.Protection of endothelial function:targets for nutritional and pHarmacological interventions.J Cardiovasc PHarmacol,2006,47:136-150.
[16]Amir Lerman,Andreas M,Zeiher.Endothelial Function:Cardiac Events.Circulation,2005,111:363-368
[17]Mosmann T.Rapid colorimetic assay for celluar growth and survival:Application to proliferation and cytotoxicity assay.J Immunol Methods,1983,65:55-63
[18]韩学杰,张立石,崔巍,沈绍功.痰瘀同治方对高脂血清损伤体外培养细胞保护作用的研究. 中国中医基础医学杂志,2002;8(12):30-33
[19]吉瑞瑞,李付英,张雪静,段重高,周亚伟.淫羊藿苷对缺氧诱导血管内皮细胞损伤的保护作用.中国中西医结合杂志,2005;25(6):525-530
[20]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响.广州中医药大学学报,2001;18(2):104-108
[21]陈云波,王奇,王培训,等.血瘀证兔模型血管内皮细胞培养的形态结构改变初探.中国中医基础医学杂志,1999;5(5):12-16
[22]温绍君,刘沾琳.血管内皮细胞功能研究概况.生殖医学杂志.2005;14(5):310-313
[23]丁品,李健.血管内皮功能障碍与冠状动脉疾病的关系及防治进展.实用心脑肺血管病杂志,2007;15(2):87-89
[24]Widasky ME,Gokce N,Keaney JF,et,al.Evidence that selective endothelial dysfunction may occur in the absence of angiograpHic or ultrasound atherosclerosis in patients with risk factory for atherosclerosis.J Am Coll Cardiol,1994,23:833-843
[25]刘月洁,吴饱君.糖尿病患者血管内皮功能损伤的发生机制.临床超声医学杂志,2003;5(1):38-40
[26]陈涛,王中心.血管内皮功能障碍与2型糖尿病.医学综述,2006;12(6):376-379
[27]Morise T,Koni I,Takeuchi Y,et al.Increased plasma levels of immuno-reactive endothelin and von Willebrand factor in non insulin dependent diabetes mellitus patients.Diabetes Care,1995,18(1):87-89.
[28]刘德庆.2型糖尿病血瘀证一氧化氮及内皮素水平变化分析.实用中医内科杂志,2007;21(3):103-105
[29]Kessler L,Wiesel ML,Attali P'et al.Von Willebrand factor in diabetic angiopathy.Diabetes Metab,1998;24(4):327-336.
[30]杨亦彬,陈忠霞,徐昆.糖尿病血管内皮损害标忠物的检测及其与尿白蛋白的关系.医师进修杂志,2005;28(5):21-23
[31]张黛莉,孙晓,时艺珊,张湘兰.2型糖尿病合并大血管病变患者GMP-140、vWF检测的意义.心血管康复医学杂志,2002;11(2):122-124.
[32]Ruggeri ZM.Structure of von willbrand factor and its function in platelet adhesion and thrombus formation.Best Pract Res Clin Haematel,2001;14:257-259
[33]丁芳林,刘丛.内皮细胞损伤标志物在2型糖尿病患者中的变化.临床医 学,2006;26(12):81-82
[34]Kim SH,Koh GY,Cho KW,et al.Stretch-activated atrial natruretic peptide secretion in atria with heat shock protein 70 over-expression.Exp Biol Med(Maywood),2003,228(2):200-206.
[35]王晓蓓,胡丽华.内皮细胞蛋白C受体功能的研究进展.国际检验医学杂志,2006;27(11):1026-1028
[36]Esmon CT.Inflammation and thrombosis.J Thromb Haemost,2003,1(7):1343-1348.
[37]Liaw PC,Neuenschwander PF,Smirnov MD,et al.Mechanisms by which soluble endothelial cell proteinC receptor modulates protein C and activated protein C function.J Biol Chem,2000,275(8):5447-5452.
[38]张旭,张超英,王文,龚婕宁.养阴药及不同配伍对VEC胞内游离钙动态变化的影响.中药药理与临床,2006;22(5)38-41
[39]张萌,张伯礼,高秀梅,郭利平,杜嵘.丹酚酸B和丹参酮ⅡA不同配比对肿瘤坏死因子损伤大鼠心脏微血管内皮细胞的影响.中草药,2004;35(1):63-65
[40]范英昌,金树梅,赵桂峰.丹参酮ⅡA对ECV-304细胞血管舒缩因子的影响.天津中医药大学学报,2006;25(4):215-218
[41]李永胜,梁黔生,王进,王照华,杨光田,郑智.丹参酮A对猪主动脉内皮细胞受血管紧张素作用时产生NO及eNOS基因表达的影响.中国中西医结合杂志,2007;27(7):637-639
[42]王奇,陈云波,梁伟雄,温泽淮,赖世隆.血瘀证兔模型血管内皮细胞内分泌功能变化及血府逐瘀汤作用的影响.中国中医基础医学杂志,1998,4(6):31
[43]陈利国,陈畅宏,屈援,聂优爱,胡小勤,何孟栖,葛红颖.血府逐瘀汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响.山东中医药大学学报,2006:30(5):395-398
[1]廖福龙.血瘀证的动物模型现状、问题与展望.中国中西医结合杂志,2002;10(2):888
[2]吴承玉.血瘀证的研究发展脉络与评述.南京中医药大学学报,2004;20(3):133-136
[3]田金洲,王永炎,时晶,朱爱华,黄启福.证候模型研究的思路北京中医药大学学报,2005;28(6):18-21
[4]李德新.中医基础理论.第1版.北京:人民卫生出版社,2001,19.
[5]陈利国,胡小勤.论病证结合血瘀证血管内皮细胞损伤模型的建立.中国中西医结合杂志,2007;27(3):271-273
[6]葛红颖,陈利国.试论《黄帝内经》对血瘀让的认识.四川中医,2003;21(12):14-15
[7]田金洲,王永炎,徐意,时晶.血瘀证动物模型的种类、评价与研究.北京中医药大学学报,2006;29(6):396-400
[8]华兴邦,庄康,孙晓进,何志娟.外伤血瘀证动物模型的研制.南京中医学院学报,1992:8(1):16-18
[9]卢振初,周淑英,罗宇慧.疼痛所致家兔“血瘀证”模型研究[J].南京中医学院学报,1991;7(3):149-150
[10]张珊珊,倪瑾,吴垦莉,柳传玲,夏友祥.寒凝血瘀证动物模型的研制[J].南京中医学院学报,1992;8(1):21-23
[11]张珊珊,吴垦莉,柳传玲,倪瑾.温经散寒和活血化瘀药物对寒凝血瘀模型的验证[J].南京中医学院学报,1993;9(2):21-23
[12]曹雪滨,李培建,黄河玲,何建成,胡元会.兔气虚血瘀型心力衰竭模型建立.实验动物科学与管理,1999;16(3):10-13.
[13]翁维良,王汀华,陈建淮.“冠心1号”对实验性微循环障碍的影响.中西医结合杂志,1982;2(3):176-177
[14]盛净,徐泽民,杨菊贤,黄震华,徐伟人,王健.灯盏细辛对犬急性心肌缺血时血小板功能、TXB_2、6-keto-PGF_2-a的影响.中华心血管病杂志,1995;23(1):53-55
[15]田鹤邨,张成英,陈前芬,储德开,杨卫东.山莨菪碱对大鼠全脑缺血/再灌注损伤的保护作用.中国循环杂志,1994;9(11):680-682
[16]张建军,傅世英,黄永麟,孟繁超,刘凤岐,陈书艳,谷宏越,李艳波,罗文涛,沈景霞.蝮蛇抗栓酶溶解冠状动脉内血栓的临床和实验研究.中华心血管病杂志,1994;22(1):30-31
[17]李麟仙,李树清,张晓霏,赵文洁.尖吻蝮蛇毒去纤酶制剂对大白鼠动、静脉血栓形成防治效应的研究.昆明医学院学报,1982;3(2):21-26
[18]赖世隆,王奇,梁伟雄;,谭芬来,温泽淮,陈云波,谢红,秦莉莉.去甲肾上腺素、牛血清白蛋白诱发血瘀证动物模型的研究.广州中医药大学学报,1993;10(4):206-211
[19]李凤文,冀向东,黄琳,霍临明,王满霞,张立石,高燕京,刘红,鄂征.家兔皮管局部血瘀模型的完善及其特异性观察.医学研究杂志,1991;20(8):15-18
[20]王昌明,何庆忠,张瑞祥.丹参酮对鼠肺纤维化过程中组织学变化的影响.中华结核和呼吸杂志,1994;17(5):308-311
[21]宋家武,李绍白.血府逐瘀汤分解方抗肝纤维化的研究.中西医结合肝病杂志,19955(2):23-25
[22]邹移海,黄韧,连至诚,等.中医实验动物学.广州:暨南大学出版社,1999:175-178
[23]尹军祥,田金洲,王永炎,宋崇顺,时晶,任映,胡泉,杨金铎.寒凝血瘀证表征模型的建立.北京中医药大学学报.2006;29(10):682-686
[24]任建勋,林成仁,王敏,林成仁,王敏,刘建勋.多因素整合建立气滞血瘀证动物模型研究.中药药理与临床.2007;23(5):210-211
[25]王键,赵辉,李净,胡建鹏,李玉梅.多因素复合制作气虚血瘀证脑缺血动物模型的实验研究.中国实验动物学报,2001;9(4):216-220
[26]李净,王键,胡建鹏,郜峦.气虚血瘀证脑缺血动物模型研究思路和方法探析.世界中西医结合杂志.2007;2(11):668-670.
[27]娄金丽,张允岭,郑宏,扈新刚,张锦,闫妍,薛利钢,黄启福.气虚血瘀证动物模型研究的思路与方法.北京中医药大学学报2006;29(2):87-90
[28]郭建队,杨秀清,陈梅.气虚血瘀证脑梗死动物模型的制作.现代中医药,2005;(3):1-3
[29]杨倩春,杨霓芝,陈伯钧,雷娓娓,王桦,马红岩.黄芪注射液对慢性肾炎气虚血瘀证大鼠模型的药效学研究.广州中医药大学学报,2004;21(3):196-200
[30]孟繁甦,陶雪飞,王大伟,潘清海.气郁血瘀型高脂动物模型的研究.中国中医急症,2005;14(9):878
[31]李会廷,谢则平.右旋糖酐-40与50%葡萄糖混合液制作动物脑血瘀证模型的实验研究.湖北省卫生职工医学院学报,2002;15(1):4-6
[32]卞慧敏,龚婕宁,魏凯峰,刘学风,俞晶华.六味地黄汤对衰老模型大鼠血液流变性的影响.中药药理与临床,2004;20(2):1-3
[33]梁爱华,杨洪军,刘建勋.血瘀证动物模型的研究概况.中国实验方剂学杂志.2003;9(2):55-58
[34]丰平,王学江.病证结合血瘀证动物模型研究.北京中医,2000;(6):52-53
[35]陈琢,黄光英,焦新福,叶望云,舒沪英.血瘀证大鼠红细胞损伤模型的研制与应用.微循环学杂志,2003;3(1):4-6
[36]杨宇飞,马麟麟,许勇刚,刘剑刚,马鲁波,王娜,林成仁.继发性红细胞增多症血瘀证病证结合动物模型的建立及清血颗粒的活血化瘀作用.中国中医基础医学杂志,2005;11(6):446-448
[37]李春阳,李林,魏海峰,张兰,赵玲.局灶性脑缺血大鼠血瘀证相关指标利脑损伤病理生理的动态变化.中国中西医结合急救杂志.2007;14(5):259-264
[38]梁爱华,丁晓霜,李文,薛宝云,王金华,杨洪军.血瘀证与血栓形成病证结合动物模型的研究.中国中药杂志,2005;30(20):1613-1616
[39]梁爱华,于长安,李春英,薛宝云,王金华,黄璐琦.内毒素与角义菜胶联合诱导的血栓形成模型的动物差异性比较.中国中药杂志,2006;31(1):57-61
[40]梁爱华,黄璐琦,于长安,薛宝云,王金华,李春英.LPS/Ca诱导血栓形成与血瘀证病证结合模型的炎症机制.中国中药杂志.2007;32(1):45-48
[41]周涛.补肾活血中药对实验性血瘀证大鼠内皮细胞功能的影响.中华中医药学刊.2007;25(9):1920-1922
[42]王春梅,乔延江.细胞模型发展现状及应用于中药研究的探讨.世界科学技术-中医药现代化.2004;6(3):29-32
[43]徐粟,丁志山,楼兰花,高承贤,宋红.血府逐瘀汤对缺氧条件下肺动脉平滑肌细胞增殖及培养液中NO水平的影响.中草药.2007;37(9):1379-1382
[44]李智,刘兰英.Cariporide对LPS诱导单核细胞与内皮细胞粘附及粘附分子表达的抑制作用.中国药理学通报.2007;23(8):1001-1006
[45]周小青,罗尧岳,谢小兵,王大安,刘旺华.五首活血化瘀方对高脂饮食所致兔动脉粥样硬化保护作用的研究.中国中医药科技.2004;11(3):148-150
[46]徐宗佩,张伯礼,高秀梅,内龙道,史红.高粘滞血症模型兔血管内皮细胞分泌功能变化及活血化瘀中药干预作用研究.山西中医.2004;20(3):44-45
[47]陈家和,顾耘.软脉煎对凝血酶诱导的家兔胸主动脉血管平滑肌细胞增生的影响.中华中医药学刊.2007;25(3):579-581
[48]朱莹,张文高,郑文娟,姜浩.脂欣康胶囊对血管平滑肌细胞源性泡沫细胞CD_(36)表达的影响.中国动脉硬化杂志.2007;15(7):481-483
[49]骆欢欢.活血化瘀法对血瘀证模型大鼠血清游离钙及血液流变学的影响.湖南中医杂志.2006;22(6):73-75
[50]张艳军,赵连根,吴咸中.活血化瘀注射液(HHI-1)对TNF-a诱发大鼠肺微血管内皮细胞粘附因子mRNA表达的影响.天津中医药.2005;22(3):240-242
[51]苏敬泽,林谦,农一兵.黄芪组分配伍对血管紧张素Ⅱ致肥大心肌细胞模型线粒体活力的影响.北京中医.2007;26(11):742-744
[52]高红梅,常文秀,曹书华.“血必净”注射液对内毒素刺激的内皮细胞的影响.中国急救医学.2005;25(6):437-438
[53]张萃,王培训,周联,董燕.活血化瘀中药对内毒素诱导THP-1细胞增殖及蛋白质组的影响.中国免疫学杂志.2006;(7):662-666
[54]韩盈,杨长春,张晓岚,包志宏,李卉,胡萍,高敏,张菁.活血化瘀药物对肝癌细胞HepG_2的抑制作用及机制.解放军药学学报.2006;22(6):401-404
[55]杨长春,韩盈,张安生,司一民,包志宏.黄芪当归及川芎嗪等活血化瘀药对肝癌细胞株HepG_2纤溶酶原激活物抑制剂1表达的影响.中国临床康复.2005;9(19):210-212
[56]李炜,孟艳冬,赵玲,丁诗语,孙莉.灯盏细辛注射液对MCF-7细胞凋亡及血管生成作用的实验研究.甘肃中医.2006;19(9):47-49
[57]梁勇,井丽萍,王珺,宋文秀,付蓉,瞿文,吴咸中.丹参酮ⅡA对初治复发及耐药人急性早幼粒细胞白血病细胞体外诱导分化作用.中华血液学杂志.2006;27(1):62-63
[58]陈云波,王奇,赖世隆.血瘀证动物细胞损伤模型的研制.广州中医药大学学报.2001;18(2):109-114
[59]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响.广州中医药大学学报,2001;18(2):105-108
[60]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响.中国实验方剂学杂志.2002;8(2):12-14
[61]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005;3(11):10-12
[62]Lerman A,Edward BS,Halltt JW,et al.Circulating and tissue endothelial immunoreactivity in advanced atherosclerosis.N Eng J Med,1991:325.997-1003.
[63]Furchgott R F,Vanhoutte PM.Endothelium-derived relaxing and contracting factors[J].FASEB J,1989,3(9):2007.
[64].Hartmann A,Aaccd M,Bing RJ.Release of endotheliumderived relaxing factor from freshly harvested porcine endothelial cells[J].Cire Res,1987,61:548.
[65]陈修.心血管药理学.第2版.北京:人民卫生出版社,1997,123.
[66]刘晓颖,李凤文,张立石,刘红,潘静华.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响[J].中国中医基础杂志,1998,4(3):15-17.
[67]谢全锦,侯灿,吴伟康,何勤.补阳还五汤对球囊扩张主动脉后再狭窄其内皮PDGFR和SOD-1基因表达的探讨.中国中西医结合杂志,1997,17(10):611-612.
[68]Biffiwl,Moore EE,Moore FA,et al.Nitri oxide reduces endothelial expression of intercellular adhesion molecule(ICAM-1).J surg Res,1996,63:328.
[69]Ling S,Dai A,Guo Z,et al.Effects a Chinese herbal preparation on vascular cells in culture mechanism of cardiovascular protection.Clin Exp PHanmacol PHysio.2005,32(7):571-578
[70]张萌,张伯礼,高秀梅,郭利平,杜嵘.丹酚酸B和丹参酮A不同配比对肿瘤坏死因子损伤大鼠心脏微血管内皮细胞的影响.中草药.2004;35(1):63-65
[71]范英昌,金树梅,赵桂峰.丹参酮ⅡA对ECV-304细胞血管舒缩因子的影响.天津中医药大学学报.2006;25(4):215-218
[72]李永胜,梁黔生,王进,王照华,杨光田,郑智.丹参酮ⅡA对猪主动脉内皮细胞受血管紧张素作用时产生NO及eNOS基因表达的影响.中国中西医结合杂志.2007;27(7):637-639
[73]崔广智,金树梅,赵桂峰,范英昌.丹参酮ⅡA对TNF-a诱导的ECV-304细胞NF-kB、IkB-a 表达及粘附分子ICAM-1、VCAM-1mRNA表达的影响.中国药理学通报.2007;23(12):1671-1675
[74]Hur JM,Shim JS,Jung H J,et al.Cryptotanshinone but not tanshi-none ⅡA inhibits angiogenesisin vitro.Exp Mol Med,2005;37(2):133-7.
[75]张知新,高福云,李克明,潘琳,董唏,陈玉武,孙瑞娟.丹参酚酸B镁对自由基损伤人主动脉内皮细胞的影响.中国中西医结合杂志,2004;24(6):521-24.
[76]陈利国,陈畅宏,屈援,聂优爱,胡小勤,何孟栖,葛红颖.血府逐瘀汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响.山东中医药大学学报.2006;30(5):395-398
[77]丁志山,高承贤,程东庆,方三华,袁巍,沃兴德.血府逐瘀汤对牛内皮细胞增殖和迁移的影响.中成药.2003;25(5):423-424
[78]张还珠,邝枣园,谭获,黄振倩.血府逐瘀汤对K562VEGF表达的影响.中药药理与临床.2007;23(4):11-13
[79]王奇,陈云波,梁伟雄,温泽淮,赖世隆.血瘀证兔模型血管内皮细胞内分泌功能变化及血府逐瘀汤作用的影响.中国中医基础医学杂志,1998,4(6):31
[1]陈可冀,马晓昌.关于传统血瘀证的现代分类.中国中西医结合杂志,2000,20(7):487
[2]余林中,吴锐.温病“微观血瘀”的证治刍议.中医研究,1996;(5):4
[3]何文彬.“瘀血”与“血瘀”辨.北京中医药大学学报,2000,23(6):14-15
[4]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005;3(11):10-12
[5]葛红颖,陈利国.试论《黄帝内经》对血瘀证的认识.四川中医,2003;21(12):14-15
[6]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响.中国实验方剂学杂志,2002;8(2):12-14
[7]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响.广州中医药大学学报,2001;18(2):104-108
[8]陈云波,王奇,王培训,程淑意,赖世隆.叶正中.血瘀证兔模型血管内皮细胞培养的形态结构改变初探.中国中医基础医学杂志,1999;5(5):12-16
[9]陈利国,胡小勤.论病证结合血瘀证血管内皮细胞损伤模型的建立.中国中西医结合杂志,2007;27(3):267-269
[10]丁品,李健.血管内皮功能障僻与冠状动脉疾病的关系及防治进展.实用心脑肺血管病杂志,2007;15(2):87-89
[11]杨少玲,单巍,韩瑞,朱旅云.2型糖尿病与内皮功能障碍,医学综述,2006;12(24):1499-1501
[12]钟秀驰,王洪琦.血瘀证的研究现状及发展思路.中医研究,1999;12(6):1-3
[13]刘军莲,宋剑南.中医血瘀证本质研究概况.辽宁中医杂志,2006;33(9):1091-1093
[14]陈利国,屈援,葛红颖,胡小勤,聂优爱,何孟栖.补阳还五汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响.中草药,2005;36(5):706-709
[15]Widasky ME,Gokce N,Keaney JF,et,al.Evidence that selective endothelial dysfunction may occur in the absence of angiograpHic or ultrasound atherosclerosis in patients with risk factory for atherosclerosis.J Am Coll Cardiol,1994,23:833-843
[16]刘月洁,吴艳君.糖尿病患者血管内皮功能损伤的发生机制.临床超声医学杂志,2003;5(1):38-40
[17]陈涛.血管内皮功能障碍与2型糖尿病.医学综述,2006;12(6):376-379
[18]Morise T,Koni I,Takeuchi Y,et al.Increased plasma levels of immuno-reactive endothelin and von Willebrand factor in non insulin dependent diabetes mellitus patients.Diabetes Care,1995,18(1):87-89.
[19]刘德庆.2型糖尿病血瘀证一氧化氮及内皮素水平变化分析.实用中医内科杂志.2007;21(3):103-105
[20]Kessler L,Wiesel ML,Attali P,et al.Von Willebrand factor in diabetic angiopathy.Diabetes Metab,1998,24(4):327-336.
[21]杨亦彬,陈忠霞,徐昆.糖尿病血管内皮损害标志物的检测及其与尿白蛋白的关系.医师进修杂志.2005;28(5):21-23
[22]张黛莉,孙晓,时艺珊,张湘兰.2型糖尿病合并大血管病变患者GMP-140、vWF检测的意义.心血管康复医学杂志,2002;11(2):122-124.
[23]Ruggeri ZM.Structure of von willbrand factor and its function in platelet adhesion and thrombus formation.Best Pract Res Clin Haematel,2001;14:257-259
[24]丁芳林,刘丛.内皮细胞损伤标志物在2型糖尿病患者中的变化.临床医学.2006;26(12):81-82
[25]Kim SH,Koh GY,Cho KW,et al.Stretch-activated atrial natruretic peptide secretion in atria with heat shock protein 70 over-expression.Exp Biol Med(Maywood),2003,228(2):200-206.
[26]王晓蓓,胡丽华.内皮细胞蛋白C受体功能的研究进展.国际检验医学杂志.2006;27(11):1026-1028
[27]Esmon CT.Inflammation and thrombosis.J Thromb Haemost,2003,1(7):1343-1348.
[28]Liaw PC,Neuenschwander PF,Smirnov MD,et al.Mechanisms by which soluble endothelial cell proteinC receptor modulates protein C and activated protein C function.J Biol Chem,2000,275(8):5447-5452.
[29]叶山东,李素梅,周志中,吴竞生,陈超,陈若平,莫蔚林.2型糖尿病病人血浆可溶性内皮细胞蛋白C受体和血栓调节蛋白的变化.中国临床保健杂志.2000;3(3):116-118
[30]Bumier M,Genteno G,Burki E,et al.Confocol microscopy to analyze cytosolic and nuclear calcium in cultured vascular cells.Am J PHysiol,1994,266(4Pt1):C1118-1127
[31]张旭,张超英,王文,龚婕宁.养阴药及不同配伍对VEC胞内游离钙动态变化的影响.中药药理与临床.2006;22(5)38-41
[32]张永伟,刘卓,左瑾,孟雁,方福德.细胞骨架与血糖调节.生命科学.2005;17(2):159-164
[33]路艳.糖尿病血瘀证的病机与辨证探析.中医药学刊,2003;21(10)
[2]吴承玉.血瘀证的研究发展脉络与评述.南京中医药大学学报,2004;20(3):133-136
[3]田金洲,王永炎,时晶,朱爱华,黄启福.证候模型研究的思路北京中医药大学学报,2005:28(6):18-21
[4]田金洲,王永炎,徐意,时晶.血瘀证动物模型的种类、评价与研究.北京中医药大学学报,2006;29(6):396-400
[5]徐丽,陈柏楠.血瘀证实验研究概况.山东中医杂志,2005;24(7):445-447
[6]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005;3(11):10-12
[7]葛红颖,陈利国.试论《黄帝内经》对血瘀证的认识.四川中医,2003;21(12):14-15
[8]刘军莲,宋剑南.中医血瘀证本质研究概况.辽宁中医杂志,2006;33(9):1091-1093
[9]陈利国,屈援,葛红颖,胡小勤,聂优爱,何孟栖.补阳还五汤对血瘀证大鼠曲.管内皮细胞黏附分子表达的影响.中草药,2005;36(5):706-709
[10]王奇,陈云波,赖世隆,梁伟雄,温汗淮.血府逐瘀汤对血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响.中国实验方剂学杂志,2002;8(2):12-14
[11]陈利国,胡小勤.论病证结合血瘀证血管内皮细胞损伤模型的建立.中国中西医结合杂志,2007;27(3):271-273
[12]蒋跃绒,殷惠军,刘颖,陈强,陈可冀.血瘀证基础研究的若干思考.中国中医基础医学杂志,2005;11(8):561-563
[13]祝湛予,郭赛珊,梁晓春.对糖尿病中医标准及施治方药的探讨.上海中医药杂志,1982,(6):5
[14]陈利国,马民,屈援,等.糖尿病血瘀证研究进展.中华中医药杂志,2005;20(2):114-116
[15]Isaballa Sudano,Lukas E Spieker,Frank Hermann,et al.Protection of endothelial function:targets for nutritional and pHarmacological interventions.J Cardiovasc PHarmacol,2006,47:136-150.
[16]Amir Lerman,Andreas M,Zeiher.Endothelial Function:Cardiac Events.Circulation,2005,111:363-368
[17]Mosmann T.Rapid colorimetic assay for celluar growth and survival:Application to proliferation and cytotoxicity assay.J Immunol Methods,1983,65:55-63
[18]韩学杰,张立石,崔巍,沈绍功.痰瘀同治方对高脂血清损伤体外培养细胞保护作用的研究. 中国中医基础医学杂志,2002;8(12):30-33
[19]吉瑞瑞,李付英,张雪静,段重高,周亚伟.淫羊藿苷对缺氧诱导血管内皮细胞损伤的保护作用.中国中西医结合杂志,2005;25(6):525-530
[20]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响.广州中医药大学学报,2001;18(2):104-108
[21]陈云波,王奇,王培训,等.血瘀证兔模型血管内皮细胞培养的形态结构改变初探.中国中医基础医学杂志,1999;5(5):12-16
[22]温绍君,刘沾琳.血管内皮细胞功能研究概况.生殖医学杂志.2005;14(5):310-313
[23]丁品,李健.血管内皮功能障碍与冠状动脉疾病的关系及防治进展.实用心脑肺血管病杂志,2007;15(2):87-89
[24]Widasky ME,Gokce N,Keaney JF,et,al.Evidence that selective endothelial dysfunction may occur in the absence of angiograpHic or ultrasound atherosclerosis in patients with risk factory for atherosclerosis.J Am Coll Cardiol,1994,23:833-843
[25]刘月洁,吴饱君.糖尿病患者血管内皮功能损伤的发生机制.临床超声医学杂志,2003;5(1):38-40
[26]陈涛,王中心.血管内皮功能障碍与2型糖尿病.医学综述,2006;12(6):376-379
[27]Morise T,Koni I,Takeuchi Y,et al.Increased plasma levels of immuno-reactive endothelin and von Willebrand factor in non insulin dependent diabetes mellitus patients.Diabetes Care,1995,18(1):87-89.
[28]刘德庆.2型糖尿病血瘀证一氧化氮及内皮素水平变化分析.实用中医内科杂志,2007;21(3):103-105
[29]Kessler L,Wiesel ML,Attali P'et al.Von Willebrand factor in diabetic angiopathy.Diabetes Metab,1998;24(4):327-336.
[30]杨亦彬,陈忠霞,徐昆.糖尿病血管内皮损害标忠物的检测及其与尿白蛋白的关系.医师进修杂志,2005;28(5):21-23
[31]张黛莉,孙晓,时艺珊,张湘兰.2型糖尿病合并大血管病变患者GMP-140、vWF检测的意义.心血管康复医学杂志,2002;11(2):122-124.
[32]Ruggeri ZM.Structure of von willbrand factor and its function in platelet adhesion and thrombus formation.Best Pract Res Clin Haematel,2001;14:257-259
[33]丁芳林,刘丛.内皮细胞损伤标志物在2型糖尿病患者中的变化.临床医 学,2006;26(12):81-82
[34]Kim SH,Koh GY,Cho KW,et al.Stretch-activated atrial natruretic peptide secretion in atria with heat shock protein 70 over-expression.Exp Biol Med(Maywood),2003,228(2):200-206.
[35]王晓蓓,胡丽华.内皮细胞蛋白C受体功能的研究进展.国际检验医学杂志,2006;27(11):1026-1028
[36]Esmon CT.Inflammation and thrombosis.J Thromb Haemost,2003,1(7):1343-1348.
[37]Liaw PC,Neuenschwander PF,Smirnov MD,et al.Mechanisms by which soluble endothelial cell proteinC receptor modulates protein C and activated protein C function.J Biol Chem,2000,275(8):5447-5452.
[38]张旭,张超英,王文,龚婕宁.养阴药及不同配伍对VEC胞内游离钙动态变化的影响.中药药理与临床,2006;22(5)38-41
[39]张萌,张伯礼,高秀梅,郭利平,杜嵘.丹酚酸B和丹参酮ⅡA不同配比对肿瘤坏死因子损伤大鼠心脏微血管内皮细胞的影响.中草药,2004;35(1):63-65
[40]范英昌,金树梅,赵桂峰.丹参酮ⅡA对ECV-304细胞血管舒缩因子的影响.天津中医药大学学报,2006;25(4):215-218
[41]李永胜,梁黔生,王进,王照华,杨光田,郑智.丹参酮A对猪主动脉内皮细胞受血管紧张素作用时产生NO及eNOS基因表达的影响.中国中西医结合杂志,2007;27(7):637-639
[42]王奇,陈云波,梁伟雄,温泽淮,赖世隆.血瘀证兔模型血管内皮细胞内分泌功能变化及血府逐瘀汤作用的影响.中国中医基础医学杂志,1998,4(6):31
[43]陈利国,陈畅宏,屈援,聂优爱,胡小勤,何孟栖,葛红颖.血府逐瘀汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响.山东中医药大学学报,2006:30(5):395-398
[1]廖福龙.血瘀证的动物模型现状、问题与展望.中国中西医结合杂志,2002;10(2):888
[2]吴承玉.血瘀证的研究发展脉络与评述.南京中医药大学学报,2004;20(3):133-136
[3]田金洲,王永炎,时晶,朱爱华,黄启福.证候模型研究的思路北京中医药大学学报,2005;28(6):18-21
[4]李德新.中医基础理论.第1版.北京:人民卫生出版社,2001,19.
[5]陈利国,胡小勤.论病证结合血瘀证血管内皮细胞损伤模型的建立.中国中西医结合杂志,2007;27(3):271-273
[6]葛红颖,陈利国.试论《黄帝内经》对血瘀让的认识.四川中医,2003;21(12):14-15
[7]田金洲,王永炎,徐意,时晶.血瘀证动物模型的种类、评价与研究.北京中医药大学学报,2006;29(6):396-400
[8]华兴邦,庄康,孙晓进,何志娟.外伤血瘀证动物模型的研制.南京中医学院学报,1992:8(1):16-18
[9]卢振初,周淑英,罗宇慧.疼痛所致家兔“血瘀证”模型研究[J].南京中医学院学报,1991;7(3):149-150
[10]张珊珊,倪瑾,吴垦莉,柳传玲,夏友祥.寒凝血瘀证动物模型的研制[J].南京中医学院学报,1992;8(1):21-23
[11]张珊珊,吴垦莉,柳传玲,倪瑾.温经散寒和活血化瘀药物对寒凝血瘀模型的验证[J].南京中医学院学报,1993;9(2):21-23
[12]曹雪滨,李培建,黄河玲,何建成,胡元会.兔气虚血瘀型心力衰竭模型建立.实验动物科学与管理,1999;16(3):10-13.
[13]翁维良,王汀华,陈建淮.“冠心1号”对实验性微循环障碍的影响.中西医结合杂志,1982;2(3):176-177
[14]盛净,徐泽民,杨菊贤,黄震华,徐伟人,王健.灯盏细辛对犬急性心肌缺血时血小板功能、TXB_2、6-keto-PGF_2-a的影响.中华心血管病杂志,1995;23(1):53-55
[15]田鹤邨,张成英,陈前芬,储德开,杨卫东.山莨菪碱对大鼠全脑缺血/再灌注损伤的保护作用.中国循环杂志,1994;9(11):680-682
[16]张建军,傅世英,黄永麟,孟繁超,刘凤岐,陈书艳,谷宏越,李艳波,罗文涛,沈景霞.蝮蛇抗栓酶溶解冠状动脉内血栓的临床和实验研究.中华心血管病杂志,1994;22(1):30-31
[17]李麟仙,李树清,张晓霏,赵文洁.尖吻蝮蛇毒去纤酶制剂对大白鼠动、静脉血栓形成防治效应的研究.昆明医学院学报,1982;3(2):21-26
[18]赖世隆,王奇,梁伟雄;,谭芬来,温泽淮,陈云波,谢红,秦莉莉.去甲肾上腺素、牛血清白蛋白诱发血瘀证动物模型的研究.广州中医药大学学报,1993;10(4):206-211
[19]李凤文,冀向东,黄琳,霍临明,王满霞,张立石,高燕京,刘红,鄂征.家兔皮管局部血瘀模型的完善及其特异性观察.医学研究杂志,1991;20(8):15-18
[20]王昌明,何庆忠,张瑞祥.丹参酮对鼠肺纤维化过程中组织学变化的影响.中华结核和呼吸杂志,1994;17(5):308-311
[21]宋家武,李绍白.血府逐瘀汤分解方抗肝纤维化的研究.中西医结合肝病杂志,19955(2):23-25
[22]邹移海,黄韧,连至诚,等.中医实验动物学.广州:暨南大学出版社,1999:175-178
[23]尹军祥,田金洲,王永炎,宋崇顺,时晶,任映,胡泉,杨金铎.寒凝血瘀证表征模型的建立.北京中医药大学学报.2006;29(10):682-686
[24]任建勋,林成仁,王敏,林成仁,王敏,刘建勋.多因素整合建立气滞血瘀证动物模型研究.中药药理与临床.2007;23(5):210-211
[25]王键,赵辉,李净,胡建鹏,李玉梅.多因素复合制作气虚血瘀证脑缺血动物模型的实验研究.中国实验动物学报,2001;9(4):216-220
[26]李净,王键,胡建鹏,郜峦.气虚血瘀证脑缺血动物模型研究思路和方法探析.世界中西医结合杂志.2007;2(11):668-670.
[27]娄金丽,张允岭,郑宏,扈新刚,张锦,闫妍,薛利钢,黄启福.气虚血瘀证动物模型研究的思路与方法.北京中医药大学学报2006;29(2):87-90
[28]郭建队,杨秀清,陈梅.气虚血瘀证脑梗死动物模型的制作.现代中医药,2005;(3):1-3
[29]杨倩春,杨霓芝,陈伯钧,雷娓娓,王桦,马红岩.黄芪注射液对慢性肾炎气虚血瘀证大鼠模型的药效学研究.广州中医药大学学报,2004;21(3):196-200
[30]孟繁甦,陶雪飞,王大伟,潘清海.气郁血瘀型高脂动物模型的研究.中国中医急症,2005;14(9):878
[31]李会廷,谢则平.右旋糖酐-40与50%葡萄糖混合液制作动物脑血瘀证模型的实验研究.湖北省卫生职工医学院学报,2002;15(1):4-6
[32]卞慧敏,龚婕宁,魏凯峰,刘学风,俞晶华.六味地黄汤对衰老模型大鼠血液流变性的影响.中药药理与临床,2004;20(2):1-3
[33]梁爱华,杨洪军,刘建勋.血瘀证动物模型的研究概况.中国实验方剂学杂志.2003;9(2):55-58
[34]丰平,王学江.病证结合血瘀证动物模型研究.北京中医,2000;(6):52-53
[35]陈琢,黄光英,焦新福,叶望云,舒沪英.血瘀证大鼠红细胞损伤模型的研制与应用.微循环学杂志,2003;3(1):4-6
[36]杨宇飞,马麟麟,许勇刚,刘剑刚,马鲁波,王娜,林成仁.继发性红细胞增多症血瘀证病证结合动物模型的建立及清血颗粒的活血化瘀作用.中国中医基础医学杂志,2005;11(6):446-448
[37]李春阳,李林,魏海峰,张兰,赵玲.局灶性脑缺血大鼠血瘀证相关指标利脑损伤病理生理的动态变化.中国中西医结合急救杂志.2007;14(5):259-264
[38]梁爱华,丁晓霜,李文,薛宝云,王金华,杨洪军.血瘀证与血栓形成病证结合动物模型的研究.中国中药杂志,2005;30(20):1613-1616
[39]梁爱华,于长安,李春英,薛宝云,王金华,黄璐琦.内毒素与角义菜胶联合诱导的血栓形成模型的动物差异性比较.中国中药杂志,2006;31(1):57-61
[40]梁爱华,黄璐琦,于长安,薛宝云,王金华,李春英.LPS/Ca诱导血栓形成与血瘀证病证结合模型的炎症机制.中国中药杂志.2007;32(1):45-48
[41]周涛.补肾活血中药对实验性血瘀证大鼠内皮细胞功能的影响.中华中医药学刊.2007;25(9):1920-1922
[42]王春梅,乔延江.细胞模型发展现状及应用于中药研究的探讨.世界科学技术-中医药现代化.2004;6(3):29-32
[43]徐粟,丁志山,楼兰花,高承贤,宋红.血府逐瘀汤对缺氧条件下肺动脉平滑肌细胞增殖及培养液中NO水平的影响.中草药.2007;37(9):1379-1382
[44]李智,刘兰英.Cariporide对LPS诱导单核细胞与内皮细胞粘附及粘附分子表达的抑制作用.中国药理学通报.2007;23(8):1001-1006
[45]周小青,罗尧岳,谢小兵,王大安,刘旺华.五首活血化瘀方对高脂饮食所致兔动脉粥样硬化保护作用的研究.中国中医药科技.2004;11(3):148-150
[46]徐宗佩,张伯礼,高秀梅,内龙道,史红.高粘滞血症模型兔血管内皮细胞分泌功能变化及活血化瘀中药干预作用研究.山西中医.2004;20(3):44-45
[47]陈家和,顾耘.软脉煎对凝血酶诱导的家兔胸主动脉血管平滑肌细胞增生的影响.中华中医药学刊.2007;25(3):579-581
[48]朱莹,张文高,郑文娟,姜浩.脂欣康胶囊对血管平滑肌细胞源性泡沫细胞CD_(36)表达的影响.中国动脉硬化杂志.2007;15(7):481-483
[49]骆欢欢.活血化瘀法对血瘀证模型大鼠血清游离钙及血液流变学的影响.湖南中医杂志.2006;22(6):73-75
[50]张艳军,赵连根,吴咸中.活血化瘀注射液(HHI-1)对TNF-a诱发大鼠肺微血管内皮细胞粘附因子mRNA表达的影响.天津中医药.2005;22(3):240-242
[51]苏敬泽,林谦,农一兵.黄芪组分配伍对血管紧张素Ⅱ致肥大心肌细胞模型线粒体活力的影响.北京中医.2007;26(11):742-744
[52]高红梅,常文秀,曹书华.“血必净”注射液对内毒素刺激的内皮细胞的影响.中国急救医学.2005;25(6):437-438
[53]张萃,王培训,周联,董燕.活血化瘀中药对内毒素诱导THP-1细胞增殖及蛋白质组的影响.中国免疫学杂志.2006;(7):662-666
[54]韩盈,杨长春,张晓岚,包志宏,李卉,胡萍,高敏,张菁.活血化瘀药物对肝癌细胞HepG_2的抑制作用及机制.解放军药学学报.2006;22(6):401-404
[55]杨长春,韩盈,张安生,司一民,包志宏.黄芪当归及川芎嗪等活血化瘀药对肝癌细胞株HepG_2纤溶酶原激活物抑制剂1表达的影响.中国临床康复.2005;9(19):210-212
[56]李炜,孟艳冬,赵玲,丁诗语,孙莉.灯盏细辛注射液对MCF-7细胞凋亡及血管生成作用的实验研究.甘肃中医.2006;19(9):47-49
[57]梁勇,井丽萍,王珺,宋文秀,付蓉,瞿文,吴咸中.丹参酮ⅡA对初治复发及耐药人急性早幼粒细胞白血病细胞体外诱导分化作用.中华血液学杂志.2006;27(1):62-63
[58]陈云波,王奇,赖世隆.血瘀证动物细胞损伤模型的研制.广州中医药大学学报.2001;18(2):109-114
[59]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响.广州中医药大学学报,2001;18(2):105-108
[60]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响.中国实验方剂学杂志.2002;8(2):12-14
[61]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005;3(11):10-12
[62]Lerman A,Edward BS,Halltt JW,et al.Circulating and tissue endothelial immunoreactivity in advanced atherosclerosis.N Eng J Med,1991:325.997-1003.
[63]Furchgott R F,Vanhoutte PM.Endothelium-derived relaxing and contracting factors[J].FASEB J,1989,3(9):2007.
[64].Hartmann A,Aaccd M,Bing RJ.Release of endotheliumderived relaxing factor from freshly harvested porcine endothelial cells[J].Cire Res,1987,61:548.
[65]陈修.心血管药理学.第2版.北京:人民卫生出版社,1997,123.
[66]刘晓颖,李凤文,张立石,刘红,潘静华.水蛭对实验性动脉粥样硬化家兔血管内皮功能障碍的影响[J].中国中医基础杂志,1998,4(3):15-17.
[67]谢全锦,侯灿,吴伟康,何勤.补阳还五汤对球囊扩张主动脉后再狭窄其内皮PDGFR和SOD-1基因表达的探讨.中国中西医结合杂志,1997,17(10):611-612.
[68]Biffiwl,Moore EE,Moore FA,et al.Nitri oxide reduces endothelial expression of intercellular adhesion molecule(ICAM-1).J surg Res,1996,63:328.
[69]Ling S,Dai A,Guo Z,et al.Effects a Chinese herbal preparation on vascular cells in culture mechanism of cardiovascular protection.Clin Exp PHanmacol PHysio.2005,32(7):571-578
[70]张萌,张伯礼,高秀梅,郭利平,杜嵘.丹酚酸B和丹参酮A不同配比对肿瘤坏死因子损伤大鼠心脏微血管内皮细胞的影响.中草药.2004;35(1):63-65
[71]范英昌,金树梅,赵桂峰.丹参酮ⅡA对ECV-304细胞血管舒缩因子的影响.天津中医药大学学报.2006;25(4):215-218
[72]李永胜,梁黔生,王进,王照华,杨光田,郑智.丹参酮ⅡA对猪主动脉内皮细胞受血管紧张素作用时产生NO及eNOS基因表达的影响.中国中西医结合杂志.2007;27(7):637-639
[73]崔广智,金树梅,赵桂峰,范英昌.丹参酮ⅡA对TNF-a诱导的ECV-304细胞NF-kB、IkB-a 表达及粘附分子ICAM-1、VCAM-1mRNA表达的影响.中国药理学通报.2007;23(12):1671-1675
[74]Hur JM,Shim JS,Jung H J,et al.Cryptotanshinone but not tanshi-none ⅡA inhibits angiogenesisin vitro.Exp Mol Med,2005;37(2):133-7.
[75]张知新,高福云,李克明,潘琳,董唏,陈玉武,孙瑞娟.丹参酚酸B镁对自由基损伤人主动脉内皮细胞的影响.中国中西医结合杂志,2004;24(6):521-24.
[76]陈利国,陈畅宏,屈援,聂优爱,胡小勤,何孟栖,葛红颖.血府逐瘀汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响.山东中医药大学学报.2006;30(5):395-398
[77]丁志山,高承贤,程东庆,方三华,袁巍,沃兴德.血府逐瘀汤对牛内皮细胞增殖和迁移的影响.中成药.2003;25(5):423-424
[78]张还珠,邝枣园,谭获,黄振倩.血府逐瘀汤对K562VEGF表达的影响.中药药理与临床.2007;23(4):11-13
[79]王奇,陈云波,梁伟雄,温泽淮,赖世隆.血瘀证兔模型血管内皮细胞内分泌功能变化及血府逐瘀汤作用的影响.中国中医基础医学杂志,1998,4(6):31
[1]陈可冀,马晓昌.关于传统血瘀证的现代分类.中国中西医结合杂志,2000,20(7):487
[2]余林中,吴锐.温病“微观血瘀”的证治刍议.中医研究,1996;(5):4
[3]何文彬.“瘀血”与“血瘀”辨.北京中医药大学学报,2000,23(6):14-15
[4]陈可冀.血瘀证与活血化瘀治疗的研究.中国中医药现代远程教育,2005;3(11):10-12
[5]葛红颖,陈利国.试论《黄帝内经》对血瘀证的认识.四川中医,2003;21(12):14-15
[6]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对血瘀证兔模型血清损伤的血管内皮细胞内分泌功能的影响.中国实验方剂学杂志,2002;8(2):12-14
[7]王奇,陈云波,赖世隆,梁伟雄,温泽淮.血府逐瘀汤对用血瘀证兔血清损伤的血管内皮细胞的形态学影响.广州中医药大学学报,2001;18(2):104-108
[8]陈云波,王奇,王培训,程淑意,赖世隆.叶正中.血瘀证兔模型血管内皮细胞培养的形态结构改变初探.中国中医基础医学杂志,1999;5(5):12-16
[9]陈利国,胡小勤.论病证结合血瘀证血管内皮细胞损伤模型的建立.中国中西医结合杂志,2007;27(3):267-269
[10]丁品,李健.血管内皮功能障僻与冠状动脉疾病的关系及防治进展.实用心脑肺血管病杂志,2007;15(2):87-89
[11]杨少玲,单巍,韩瑞,朱旅云.2型糖尿病与内皮功能障碍,医学综述,2006;12(24):1499-1501
[12]钟秀驰,王洪琦.血瘀证的研究现状及发展思路.中医研究,1999;12(6):1-3
[13]刘军莲,宋剑南.中医血瘀证本质研究概况.辽宁中医杂志,2006;33(9):1091-1093
[14]陈利国,屈援,葛红颖,胡小勤,聂优爱,何孟栖.补阳还五汤对血瘀证大鼠血管内皮细胞黏附分子表达的影响.中草药,2005;36(5):706-709
[15]Widasky ME,Gokce N,Keaney JF,et,al.Evidence that selective endothelial dysfunction may occur in the absence of angiograpHic or ultrasound atherosclerosis in patients with risk factory for atherosclerosis.J Am Coll Cardiol,1994,23:833-843
[16]刘月洁,吴艳君.糖尿病患者血管内皮功能损伤的发生机制.临床超声医学杂志,2003;5(1):38-40
[17]陈涛.血管内皮功能障碍与2型糖尿病.医学综述,2006;12(6):376-379
[18]Morise T,Koni I,Takeuchi Y,et al.Increased plasma levels of immuno-reactive endothelin and von Willebrand factor in non insulin dependent diabetes mellitus patients.Diabetes Care,1995,18(1):87-89.
[19]刘德庆.2型糖尿病血瘀证一氧化氮及内皮素水平变化分析.实用中医内科杂志.2007;21(3):103-105
[20]Kessler L,Wiesel ML,Attali P,et al.Von Willebrand factor in diabetic angiopathy.Diabetes Metab,1998,24(4):327-336.
[21]杨亦彬,陈忠霞,徐昆.糖尿病血管内皮损害标志物的检测及其与尿白蛋白的关系.医师进修杂志.2005;28(5):21-23
[22]张黛莉,孙晓,时艺珊,张湘兰.2型糖尿病合并大血管病变患者GMP-140、vWF检测的意义.心血管康复医学杂志,2002;11(2):122-124.
[23]Ruggeri ZM.Structure of von willbrand factor and its function in platelet adhesion and thrombus formation.Best Pract Res Clin Haematel,2001;14:257-259
[24]丁芳林,刘丛.内皮细胞损伤标志物在2型糖尿病患者中的变化.临床医学.2006;26(12):81-82
[25]Kim SH,Koh GY,Cho KW,et al.Stretch-activated atrial natruretic peptide secretion in atria with heat shock protein 70 over-expression.Exp Biol Med(Maywood),2003,228(2):200-206.
[26]王晓蓓,胡丽华.内皮细胞蛋白C受体功能的研究进展.国际检验医学杂志.2006;27(11):1026-1028
[27]Esmon CT.Inflammation and thrombosis.J Thromb Haemost,2003,1(7):1343-1348.
[28]Liaw PC,Neuenschwander PF,Smirnov MD,et al.Mechanisms by which soluble endothelial cell proteinC receptor modulates protein C and activated protein C function.J Biol Chem,2000,275(8):5447-5452.
[29]叶山东,李素梅,周志中,吴竞生,陈超,陈若平,莫蔚林.2型糖尿病病人血浆可溶性内皮细胞蛋白C受体和血栓调节蛋白的变化.中国临床保健杂志.2000;3(3):116-118
[30]Bumier M,Genteno G,Burki E,et al.Confocol microscopy to analyze cytosolic and nuclear calcium in cultured vascular cells.Am J PHysiol,1994,266(4Pt1):C1118-1127
[31]张旭,张超英,王文,龚婕宁.养阴药及不同配伍对VEC胞内游离钙动态变化的影响.中药药理与临床.2006;22(5)38-41
[32]张永伟,刘卓,左瑾,孟雁,方福德.细胞骨架与血糖调节.生命科学.2005;17(2):159-164
[33]路艳.糖尿病血瘀证的病机与辨证探析.中医药学刊,2003;21(10)
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |